Powder Or Dust Containing Patents (Class 424/46)
  • Patent number: 9072783
    Abstract: A method for the selection of pharmaceutically acceptable excipients that allow for the production of highly dispersible powders produced by spray drying.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: July 7, 2015
    Assignee: Aridis Pharmaceuticals
    Inventors: Satoshi Ohtake, Atul Saxena, Vu Truong-Le
  • Patent number: 9061352
    Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: June 23, 2015
    Assignee: Pulmatrix, Inc.
    Inventors: Michael M. Lipp, Jean C. Sung
  • Publication number: 20150139917
    Abstract: The invention relates to an aerosol device which contains a cosmetic composition comprising: (i) one or more sebum-absorbing powders with a sebum uptake of greater than or equal to 35 ml/100 g, (ii) a water-insoluble mineral compound which is calcium carbonate, (iii) one or more C2-4 monoalcohols, and (iv) one or more propellants. Another aerosol device of the invention contains a cosmetic composition comprising: (i) one or more sebum-absorbing powders with a sebum uptake of greater than or equal to 35 ml/100 g, (ii) one or more water-insoluble mineral compounds chosen from metal carbonates, oxides and sulfates and silicates containing magnesium, (iii) one or more C2-4 monoalcohols, (iv) one or more propellants, and (v) one or more silicone gums having a viscosity of greater than 0.5×10?3 m2/s (500 cSt). The invention also relates to a process for the dry washing and cosmetic treatment of keratin materials, and more particularly of the hair, using the aerosol devices of the invention.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 21, 2015
    Inventors: Jonathan Gawtrey, Nadia Smail
  • Patent number: 9011923
    Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: April 21, 2015
    Assignees: Innovata Biomed Limited, Vectura Limited
    Inventors: David Andrew Lewis, Christina Alexandra Keeble, Nicola Kim Whitfield, Tanya Church
  • Patent number: 8986659
    Abstract: A diamond dust polishing agent for home use and professional use in the care of natural tooth enamel and dental veneers comprised of a quantity of diamond dust coated with a lubricant in conjunction with a paste for carrying the lubricant coated diamond dust, or other semi-precious, non-toxic abrasive dust, said diamond dust being of a size of approximately 500 nanometers or less to a size of approximately 5 nanometers. The size of the dust of both the diamond and the semi-precious stone may vary, depending on the degree of abrasiveness and the lubricant employed. The diamond dust (and semi-precious dust) polishing agent permits the user to maintain the polish and luster of the natural tooth enamel and veneer at home without adversely abrading or damaging the surface thereof.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: March 24, 2015
    Assignee: Wam Oral Care Products, LLC
    Inventor: Michael Herman
  • Patent number: 8980226
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 17, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Patent number: 8974828
    Abstract: Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: March 10, 2015
    Assignee: InCarda Therapeutics, Inc.
    Inventors: Carlos A. Schuler, Rangachari Narasimhan
  • Patent number: 8955512
    Abstract: The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10? thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method comprises: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: February 17, 2015
    Assignee: Alexza Pharmaceuticals, Inc.
    Inventors: Ron L. Hale, Craig C. Hodges, Peter M. Lloyd, Daniel Mufson, Daniel D. Rogers, Soonho Song, Martin J. Wensley, Daniel J. Myers, Jeffrey A. McKinney, Reynaldo J. Quintana, Joshua D. Rabinowitz
  • Patent number: 8940333
    Abstract: An amphiphilic block copolymer is disclosed. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nanoparticle and carrier including the amphiphilic block copolymer for delivery of water insoluble drugs, growth factors, genes, or water insoluble cosmetic substances.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 27, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Ming-Fa Hsieh, Hsuen-Tseng Cha'ng, Chin-Fu Chen, Yuan-Chia Chang, Pei Kan, Tsai-Yu Lin
  • Patent number: 8940319
    Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: January 27, 2015
    Assignee: Accentia Biopharmceuticals, Inc.
    Inventors: Francis E. O'Donnell, Angelos M. Stergiou
  • Patent number: 8932635
    Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 13, 2015
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, Haggis Harris, David Alexander Vodden Morton, Robin Bannister
  • Publication number: 20150010633
    Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Applicant: Luxena Pharmaceuticals, Inc.
    Inventors: Xiaodong LI, George Lu
  • Patent number: 8920781
    Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material in the powder has been found to give an increased respirable fraction of the active material.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: December 30, 2014
    Assignee: Vectura Limited
    Inventor: John Nicholas Staniforth
  • Publication number: 20140377190
    Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Application
    Filed: April 21, 2014
    Publication date: December 25, 2014
    Applicant: Pearl Therapeutics, Inc.
    Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Dwivedi
  • Patent number: 8912174
    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: December 16, 2014
    Assignee: Mylan Pharmaceuticals Inc.
    Inventor: Imtiaz Chaudry
  • Patent number: 8887715
    Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: November 18, 2014
    Assignee: Civitas Therapeutics, Inc.
    Inventor: Jeffrey S. Hrkach
  • Patent number: 8889105
    Abstract: A respirable composition for treatment of a bacterial infection includes one or more active bacteriophages in combination with a pharmaceutically acceptable respirable carrier. The composition includes a carbohydrate carrier, and is prepared as fine powder. In another aspect, bacteriophages are provided in a liquid carrier for administration by nebulization. In one aspect, the bacteriophages have anti-bacterial activity against one or more species or strains of Burkholderia cepacia complex (BCC) bacteria. The invention further relates to the use of a BCC bacteriophage to treat a BCC infection, in particular in an individual suffering from cystic fibrosis.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: November 18, 2014
    Inventors: Warren H. Finlay, Jonathan J. Dennis, Helena Orszanska, Kimberley D. Seed, Karlene Heather Lynch
  • Publication number: 20140322142
    Abstract: A stable crystalline micronized particulate of a glycopyrronium salt may be prepared by suspending the drug in a water-immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 30, 2014
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Irene PASQUALI, Andrea Casazza, Elena Losi, Mark Saunders
  • Patent number: 8871274
    Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: October 28, 2014
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
  • Publication number: 20140311482
    Abstract: The disclosure describes an aerosolizer with (i) means sized for intranasal or paranasal insertion that produces an aerosol from a material for delivery in close proximity to the upper airways, and (ii) the material comprising one or more proinflammatory cytokine inhibitor(s).
    Type: Application
    Filed: January 24, 2014
    Publication date: October 23, 2014
    Inventor: Roy C. Levitt
  • Patent number: 8858917
    Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: October 14, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Howard A. Stone
  • Patent number: 8834849
    Abstract: The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant and 6 to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant. Canisters suitable for delivering such a pharmaceutical formulation are also provided.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: September 16, 2014
    Assignee: Norton Healthcare Limited
    Inventor: Fiona Catherine Millar
  • Patent number: 8828359
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: September 9, 2014
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 8808713
    Abstract: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting ?2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: August 19, 2014
    Assignee: Pearl Thereapeutics, Inc.
    Inventors: Reinhard Vehring, Michael Steven Hartman, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
  • Patent number: 8802149
    Abstract: Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 12, 2014
    Assignee: Novartis Pharma AG
    Inventors: Marc S. Gordon, Andrew Clark, Thomas K. Brewer
  • Patent number: 8791226
    Abstract: The present invention generally relates to the large-scale (e.g., greater than 1 kg scale) preparation of low molecular weight polylysine or polyornithine in high yield by preparing a polylysine or polyornithine having a weight average molecular weight from about 12,500 Daltons to about 22,000 Daltons and hydrolyzing it to produce a polylysine or polyornithine having a weight average molecular weight from about 5,500 Daltons to about 12,000 Daltons.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: July 29, 2014
    Assignee: Sigma-Aldrich Co. LLC
    Inventor: Ettigounder Ponnusamy
  • Patent number: 8759369
    Abstract: An inhalable medicament is provided, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least ?50° C., such as a sugar and/or sugar alcohol.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: June 24, 2014
    Assignee: Norton Healthcare Ltd.
    Inventor: Xian-Ming Zeng
  • Patent number: 8758728
    Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: June 24, 2014
    Assignee: Stiefel Research Australia Pty Ltd
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Patent number: 8747813
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: June 10, 2014
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 8715624
    Abstract: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9?-fluoro-11?-hydroxy-16?-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: May 6, 2014
    Assignee: Taro Pharmaceuticals North America, Inc.
    Inventors: Srinivasa Rao, Suresh Dixit, Avraham Yacobi, Arthur Bailey
  • Patent number: 8715623
    Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 6, 2014
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
  • Patent number: 8709484
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders may include a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Jeffry G. Weers, Thomas E. Tarara, Luis A. Dellamary, Jean G. Riess, Ernest G. Schutt
  • Patent number: 8703806
    Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 22, 2014
    Assignee: Pearl Therapeutics, Inc.
    Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Jumar Dwivedi
  • Patent number: 8703158
    Abstract: The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: April 22, 2014
    Assignee: Biocopea Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 8679512
    Abstract: Topically administering a propellant-free formulation as a spray in the form of aqueous suspension of drug particles, wherein said formulation consists essentially of: micronized particles of beclometasone dipropionate (BDP) suspended in an aqueous phase, said aqueous phase comprising: an emulsifying agent selected from the class of polysorbates in an amount of 0.1 to 0.2% w/v, based on the total volume of the formulation; a sugar or a sugar alcohol in an amount of 5.0 to 5.2% w/v, based on the total volume of the formulation; a mixture of microcrystalline cellulose and carboxymethylcellulose sodium in an amount of 0.5 to 1.0% w/v, based on the total volume of the formulation; one or more preservatives; and water up to 100%, is effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: March 25, 2014
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventor: Salvatore Criscione
  • Patent number: 8663695
    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 4, 2014
    Assignee: Mylan Specialty L.P.
    Inventor: Imtiaz Chaudry
  • Publication number: 20140037697
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
    Type: Application
    Filed: June 3, 2013
    Publication date: February 6, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Andreas KORDIKOWSKI, Stephen Ernest WALKER, Peter YORK
  • Patent number: 8636983
    Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: January 28, 2014
    Assignee: Cardeas Pharma Inc.
    Inventor: Alan Bruce Montgomery
  • Patent number: 8636984
    Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: January 28, 2014
    Assignee: Cardeas Pharma Inc.
    Inventor: Alan Bruce Montgomery
  • Patent number: 8628754
    Abstract: A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: January 14, 2014
    Assignee: Civitas Therapeutics, Inc.
    Inventors: David A. Edwards, Richard P. Batycky, Lloyd Johnston
  • Patent number: 8603439
    Abstract: The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: December 10, 2013
    Assignee: Cardeas Pharma Inc.
    Inventor: Alan Bruce Montgomery
  • Patent number: 8597616
    Abstract: The present disclosure relates to systems, methods, and formulations for the pulmonary administration of one or more therapeutic agents, in dry powder form, in a single, large dose quantity. These formulations, methods, and systems are useful in the treatment of patients suffering from toxic or harmful gas exposure, such as nerve gas exposure, as well as in the treatment of patients suffering from diseases of the pulmonary system, including tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: December 3, 2013
    Assignee: Board of Regents of the University of Texas System
    Inventors: Edward R. Kraft, Stephen L. Hoskins, Perenlei Enkhbaatar, Daniel L. Traber
  • Patent number: 8591866
    Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: November 26, 2013
    Assignee: Pulmatrix, Inc.
    Inventors: David A. Edwards, Jonathan Chun-Wah Man, Jeffrey P. Katstra, Robert W. Clarke
  • Patent number: 8592036
    Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: November 26, 2013
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Florian Niklas Ludwig, Stephen D. Pacetti, Syed F. A. Hossainy, Dariush Davalian
  • Patent number: 8591954
    Abstract: The present invention includes a method for delivering medications deeper into the lungs and to the medications' pulmonary targets, which include bronchioles and alveoli. A first particularly preferred embodiment of the invention describes the use of two steps for delivery of a medication. In a first step, an aerosolized therapeutic composition or medication is administered into a patient's respiratory tract, wherein the patient may be any animal or human subject. Following the first step, an aerosolized surfactant is administered into the patient's respiratory tract that facilitates delivery of the aerosolized medication of the first step to the medication's pulmonary target. Another embodiment of the present invention contemplates an apparatus for the delivery of an aerosolized surfactant used that facilitates delivery of previously inhaled aerosolized medication.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: November 26, 2013
    Assignee: Next Breath, LLC
    Inventors: Shailaja Somaraju, Julie Suman, Sudipta Ganguly, Richard Dalby
  • Patent number: 8584670
    Abstract: Methods, pharmaceutical compositions, and systems are provided which include a method for treating a pulmonary viral infectious disease in a subject. The method includes administering a pharmaceutical composition including at least one agent to a pulmonary tissue of the subject, wherein the pharmaceutical composition is administered as two or more distinct and non-overlapping particle size ranges configured to contact two or more levels of pulmonary tissue of the subject, wherein the at least one agent is configured to achieve a selected pH range in the two or more levels of pulmonary tissue of the subject.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: November 19, 2013
    Assignee: Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Dennis J. Rivet, Lowell L. Wood, Jr., Victoria Y. H. Wood
  • Patent number: 8586093
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: November 19, 2013
    Assignee: Civitas Therapeutics
    Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Patent number: 8580306
    Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 ?m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolization of a dry, powder in a dry powder inhaler.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: November 12, 2013
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton
  • Patent number: 8575349
    Abstract: The present invention relates to novel derivatives of 1-alkyl-6-oxo-piperidine-3-carboxylic acids and 1-alkyl-5-oxo-pyrrolidine-3-carboxylic acids represented by Formula I: wherein n is an integer of 1 or 2; R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen and methyl; X is selected from the group consisting of oxygen and nitrogen; and R5 is hydrogen or a C1-C7 linear or branched acyclic hydrocarbon group, or R5 together with X form a 3- to 8-membered heterocyclic hydrocarbon group, and their uses as cooling compounds.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: November 5, 2013
    Assignee: International Flavors & Fragrances Inc.
    Inventor: Arkadiusz Kazimierski
  • Patent number: 8545817
    Abstract: Disclosed herein is a cosmetic composition for the treatment of keratinous fibers, for example, human keratinous fibers, such as the hair, in the form of an aerosol comprising at least one polysaccharide of lambda-carrageenan type and carbon dioxide as propellant. Also disclosed herein is a cosmetic treatment method for keratinous fibers comprising applying such a composition to the keratinous fibers.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: October 1, 2013
    Assignee: L'Oreal
    Inventors: Régis Beitone, Ludivine Laurent